Search results
Contact Information. John G. Clohessy, PhD, Director, Preclinical Murine Pharmacogenetics Core Facility. Beth Israel Deaconess Medical Center. 330 Brookline Avenue, CLS 402. Boston, MA 02215. P 617-735-2147. F 617-735-2120. Email Us.
- In Vitro Target Validation
Target validation of agents or combinations of agents in...
- Services
John G. Clohessy, PhD Director, Preclinical Murine...
- How This Will Work
John G. Clohessy, PhD. Director, Preclinical Murine...
- In Vivo Protocol Design and Implementation
John G. Clohessy, PhD. Director, Preclinical Murine...
- Mission of The Facility
This facility will work as a resource specializing in...
- From Mouse to Human: History
Acute promyelocytic leukemia (APL) is associated with the...
- In Vitro Target Validation
John CLOHESSY | Cited by 4,234 | of Beth Israel Deaconess Medical Center, Boston (BIDMC) | Read 101 publications | Contact John CLOHESSY.
John (Seán) Clohessy, PhD Beth Israel Deaconess Medical Center Phone: (617) 735-2147 Fax: (617) 735-2120 jclohess@bidmc.harvard.edu
John G. Clohessy's 4 research works with 308 citations and 847 reads, including: Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Assistant Professor. Apr 2021 - Present 3 years 1 month. Boston, Massachusetts, United States. Instructor In Medicine. Nov 2012 - Mar 2021 8 years 5 months. Greater Boston Area. Postdoctoral...
- Harvard Medical School